Print Page  |  Contact Us  |  Sign In
John Cangelosi, MD
Share |

Dr. John Cangelosi received his medical degree at the University of Texas Health Science Center at Houston after which he successfully completed an AP/CP pathology residency and dermatopathology fellowship at the University of Texas Medical Branch (Galveston, TX). Dr. Cangelosi is board-certified in dermatopathology by both the American Board of Dermatology and the American Board of Pathology. After dermatopathology board certification, Dr. Cangelosi founded Sagis, PLLC, an entirely physician-owned subspecialty diagnostic pathology laboratory located in Houston, TX. Sagis, PLLC has rapidly grown to be one of the largest dermatopathology laboratories in Texas.

Dr. Cangelosi has performed research in such topics as cutaneous adnexal tumors, histiocytic tumors, cutaneous t-cell lymphomas and non-melanoma skin cancers, and has published in various pathology journals including the American Journal of Dermatopathology, Journal of Cutaneous Pathology and Archives of Pathology and Laboratory Medicine. He has also written a book chapter about cutaneous tumors in Dermatology, A Pictorial Review (McGraw-Hill Medical Publishing). Dr. Cangelosi currently holds academic positions at both the University of Texas Medical Branch and the University of North Texas/TCOM and regularly teaches dermatopathology to both pathology and dermatology residents at numerous residency programs in Texas. Dr. Cangelosi currently holds medical licenses in numerous states including Texas, Indiana, Utah, Arizona, Florida, Oklahoma, Kansas, Illinois and Louisiana. He also holds professional membership in numerous medical societies including the American Academy of Dermatology, The American Society of Dermatopathology, College of American Pathologists, United States and Canadian Academy of Pathology and the American Medical Association.

Benign or Malignant: What Does the Pathology Say?


  1. Inform audience that clinically benign lesions can sometimes end up malignant histologically
  2. Inform audience that it is important to have low threshold for biopsy if lesion is rapidly growing or long standing and recently changed
  3. Discuss as much clinical information as possible and ensure optional clinical-pathologic correlation


  1. New methods of diagnosis or treatment.
  2. Advances in medical knowledge.


Scaly Erythematous Lesion in a patient with extensive solar damage. Malignant Melanoma In-Situ, amelanotic type.  Arch Dermatol. 1996 Oct;132(10):1239,1242.

Acneiform Primary Cutaneous CD4-positive small/medium pleomorphic T-cell lymphoma with prominent necrosis. J. Cutan Pathol, 2015 Apr;42(4):265-70.

Core Competencies: 2, 3, 4, 6

Disclosures: Sagis, PLLC

Community Search
Sign In

Forgot your password?

Haven't registered yet?

Latest News